We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Oscillating Pulsed Electric Fields Strike Major Blow to Resistant Bacteria and Cancer

By LabMedica International staff writers
Posted on 29 Oct 2013
Print article
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Image: Time lapse photos of three leukemia cells being treated with OPEF. Two of the three cells are literally shattered by the treatment (Photo courtesy of PRNewsFoto/Novobiotronics Inc.).
Oscillating pulsed electric field (OPEF) technology is delivering a one-two punch against cancer and antibiotic-resistant bacteria using a pulsed electronic signal that destroys cancer cells and disables antibiotic resistance in deadly methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas bacteria.

Novobiotronics (Saratoga Springs, NY, USA), a world leader in research on the biologic effects of OPEFs as a future nontoxic medical treatment, was the first company to confirm the capability of OPEFs to destroy 30%–60% of leukemia cells. In laboratory research, OPEF also demonstrated an ability to slow cancer growth by up to 60%. OPEF has also shown an ability to disarm antibiotic resistance in the lethal bacteria MRSA, rendering it susceptible to typically available antibiotics as well as inhibiting its growth.

Novobiotronics Inc., a nonprofit educational and scientific research, has report a significant breakthrough in the battle against cancer and harmful antibiotic-resistant strains of bacteria including the “superbug” deadliness of MRSA, and Pseudomonas aeruginosa (PS).

Anthony Holland, president of Novobiotronics, reported the findings of recent laboratory research done in collaboration with the State University of New York (Stony Brook, USA) that their new electronic treatment of antibiotic resistant MRSA and PS has both a bacteriostatic effect as well as a bactericidal effect when used in combination with tiny amounts of conventional antibiotics to which the deadly organisms are otherwise normally resistant.

The current standard medical treatment of antibiotic-resistant bacterial infections utilizes combinations of different types of antibiotics, but those combinations can result in very serious and even dangerous side effects. Physicians even induce some patients into a coma to reduce the severity of the drug side effects.

Novobiotronics’ new technology involves the use of a “plasma antenna,” a type of a helium gas filled fluorescent light used to broadcast oscillating pulsed electric fields at cancer cells and bacteria. These OPEFs can kill cancer cells, slow the growth rate of the cancer cells and bacteria greatly, and actually quash the bacteria’s ability to resist antibiotics. When used in combination with very small amounts of a traditional antibiotic, OPEF has demonstrated an ability to destroy MRSA and PS bacteria.

Novobiotronics’ collaborators from the State University of New York presented their joint findings at a September 2013 meeting of the American Society for Microbiology, held in Denver (CO, USA).

Related Links:

Novobiotronics
State University of New York


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Unstirred Waterbath
HumAqua 5

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.